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ABSTRACT 
Objective: The purpose of this study was to prepare non-effervescent floating extended release matrix of Tramadol hydrochloride using 
polyethylene oxide (PEO) and a combination of cationic and anionic polymethacrylates polymers, Eudragit® EPO (EE) and Eudragit®
Methods: Polymethacrylate polymer mixtures (PPM) in different polymer weight ratios (1:2, 1:1 and 2:1) were prepared by hot melt mixing 
process. Thermally treated PPM were evaluated by differential scanning calorimetry and fourier transform infrared spectroscopy for possible 
interpolyelectrolyte complex formation. The formulation variables like effects of polymethacryate ratios and their concentration, polymer types, 
PEO concentrations and compression force on release characteristics were investigated. The tablets were also evaluated for physicochemical 
properties,in vitro floating ability (floating lag-time and duration) and swelling properties.  
 L100-55 (EL).  
Results: The optimized formulation with the combination of PEO and PPM (F4) showed instant floating properties, extended drug release 
properties for 14h and tablet remained buoyant for >24 h. Significant difference was observed in the effect of pH of dissolution media on drug 
release from formulations prepared using combination of PEO and PPM. The dissolution data of these matrices were fitted to different dissolution 
models. Non- Fickian release transport was confirmed as the drug release mechanism from the optimized formulation (F4). 
Conclusion: non- effervescent floating tablets were found a feasible approach for the sustained-release preparation of drugs, which have limited 
absorption sites in the stomach 
Keywords: Floating, Extended Release, Polymethacrylates, Polyethylene oxide. 
 
INTRODUCTION 
The real challenge in the development of an oral controlled-release 
drug delivery system is not just to sustain the drug release but also 
to prolong the presence of the dosage form within the 
gastrointestinal tract (GIT) until all the drug is completely released 
at the desired period of time [1]. In recent years, oral dosage forms 
for gastric retention have received significant interest for their 
theoretical advantage in permitting control over the time and site of 
drug release[2]. Several approaches have been reported in the 
literature for the formulation of gastro retentive drug delivery 
systems: mucoadhesion [3, 4], flotation[5], sedimentation[6] 
,expansion[7] and modified shape systems[8,9]. Both single-unit 
systems (tablets or capsules) and multiple-unit systems 
(multiparticulate systems) have been reported in the 
literature[10,11].  
A floating drug delivery system is of particular interest for drugs 
which: (a) act locally in the stomach;(b) are primarily absorbed in 
the stomach; (c) are poorly soluble at an alkaline pH; (d) have a 
narrow window of absorption; and (e) are unstable in the intestinal 
or colonic environment[12]. Floating systems are either based on an 
inherently low density or on effervescence. Non-effervescent 
systems have their inherent low density due to the entrapment of 
air, as in the formation of low density hollow microballons [13], 
microspheres [14],incorporation of low density material (sponges) 
[15,16] or due to swelling [17]. The effervescent systems, on the 
other hand, have an initially high density, which decreases upon 
contact with the acidic environment due to CO2
Polyethylene oxide (PEO) is a high molecular weight, nonionic 
homopolymer of ethylene oxide with good water solubility. PEOs 
have been proposed as alternatives to cellulose or other ethylene 
glycol derivatives in the production of controlled release drug 
delivery system [20]. PEO, in presence of water or gastric juices, 
controls the release of the active moiety either by swelling or by 
swelling/erosion by forming a hydrogel. In this study, high 
molecular weight PEO (mw = 7×10
 generation. This is 
achieved by the incorporation of effervescent components such as 
sodium bicarbonate or sodium carbonate, and additionally citric or 
tartaric acid [18]. However, a potential problem with this system is 
that the tablet could rapidly exit the stomach before becoming 
buoyant since the device cannot float immediately after 
administration and its buoyancy will be influenced by fluctuations in 
the pH of the gastric fluids. In fact, it has been reported that the 
gastric pH elevates to approximately 5 during a meal [19]. 
Furthermore, the fasted gastric pH for an achlorhydric subject has 
been reported to be approximately 7; thus, for such patients, this 
system would not provide adequate therapy [19]. 
6
Polymethacrylates (Eudragits
) was used since it is reported 
that it swells to a greater extent and forms a stronger gel that is less 
prone to erosion. Further it also has mucoadhesive properties which 
may assist prolonging the gastric residence time [21]. The drug 
release rate from hydrophilic matrix can be modified by altering the 
polymer type, solubility of drug, polymer content, particle size of 
drug and polymer as well as types and amount of filler used in the 
formulation [22]. The adjustment of polymer concentration, 
viscosity grade and addition of different types and levels of 
excipients to the polymer matrix can modify the kinetics of drug 
release [23].  
®) are synthetic cationic or anionic 
polymers of dimethyl-aminoethylmethacrylates, methacrylic acid, 
and methacrylic acid esters in varying ratios. Several different types 
of Eudragits® are commercially available and may be obtained as dry 
powder, granules, aqueous dispersion, or as an organic solution. 
Eudragit® polymers have been proven to be suitable for a wide 
variety of pharmaceutical applications; they are primarily used in 
oral capsule and tablet as film-coating agents for protective 
purposes and provide delayed and sustained release formulations 
[24-26]. Eudragit® EPO (EE), a cationic polymer prepared by 
copolymerization of butyl methacrylate, 2-
dimethylaminoethylmethacrylate, and methyl methacrylate with 
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molar ratio of 1:2:1. This polymer is used for protective coatings and 
taste-masking [27]. It is soluble in gastric fluid below pH 5. 
Eudragit®
Few papers were devoted to the possibility of involving mixtures of 
anionic and cationic polymethacrylate polymers in an ionic 
interaction in order to prepare a new complex. This complex has pH-
independent characteristics which can be used in sustained release 
solid dosage forms [29-31]. Although polymethacrylates are widely 
used in pharmaceutical delivery systems for sustained drug release, 
their use in floating sustained release matrix tablets for local drug 
delivery in the stomach was not routinely addressed in the 
literature. Bani-Jaber et al., [32]investigated a floating drug delivery 
system consisting of sodium bicarbonate as an effervescent agent 
and combination of polymethacrylates (EL and Eudragit
 L100-55 (EL) is an anionic copolymer based on 
methacrylic acid and ethyl acrylate. It exhibits pH dependent 
solubility and is soluble at pH values higher than 5.5 [28]. 
® E100) 
polymers. Fukuda et al., [33]investigated the influence of sodium 
bicarbonate on the physicochemical properties of controlled release hot 
melt extruded (HME) tablets containing Eudragit®
In this current study, non effervescent based floating sustained 
release matrix tablets were prepared using two oppositely charged 
polymethacrylates (EL and EE) with combination of hydrophilic 
polymer as sustained release carrier. Eudragit
 RSPO and/or EE.  
® polymers were 
thermally treated and incorporated into tablets to achieve a rapid 
and pH independent floating systems, preventing premature 
evacuation through the pyloric sphincter, an inevitable event 
observed with gas-generating systems [34]. Investigations of the 
release mechanistics, as well as thermal behavior and molecular 
interaction of Eudragit® polymer blends were done to elucidate the 
degree of interaction between Eudragit®
MATERIALS AND METHODS 
 polymers which could 
govern the physical, mechanical and buoyancy properties of the 
formulated tablets. Tramadol hydrochloride, a highly water soluble 
drug, is used as a model drug. 
Materials 
Tramadol hydrochloride was obtained from matrix laboratories 
limited (Hyderabad, India) as a gift sample. EE and EL were 
purchased from EvonikRöhm GmbH (Darmstadt, Germany). 
Polyethylene oxide (PEO) was purchased from the Dow chemical 
company (USA). HPMC and Xanthan gum was obtained as gift 
samples from Matrix laboratories limited (Hyderabad, India). 
Magnesium stearate was purchased from Avantor (USA) 
Methods 
Thermal treatment of Eudragit®
The polymethacrylate polymer mixture (PPM) containing EE and EL 
in various weight ratios (1:2, 1:2, 2:1) was prepared by mixing them 
in a stainless steel container at 100°C using a thermostatic heating 
oil bath (Vision Lab Equipments, India). The resulting homogenous 
preparations were allowed to cool at room temperature and passed 
through #30 mesh ASTM sieve and kept in a HDPE bottle until use. 
 Polymers  
Characterization of PPM 
Differential scanning calorimetry 
The thermo grams of Tramadol hydrochloride, EE, EL, thermal 
treated PPM and physical mixture of drug and PPM (1:1) were 
recorded using a DSC 822e calorimeter (Mettler Toledo, Greifensee, 
Switzerland). The powders (weight 2–6 mg) were analyzed in 
analyzed in closed aluminium sample pans and the samples were 
heated from 30 to 300°C at 10 °C min-
Fourier Transform Infrared Spectroscopy. 
1. 
Infrared spectra of Tramadol hydrochloride, EE, EL, PEO, thermal 
treated PPM and physical mixture of drug and excipients (1:1) were 
recorded on Fourier transform infrared (FT-IR) instrument 
(PerkinElmer,USA) Samples were prepared and compressed with 
KBr on Minipress (Techno search, India) to form a disk. The 
compressed disks were scanned over 400 to 4,000 cm−1, and 
characteristic peaks were recorded and evaluated. 
Preparation of Floating Matrix Tablets 
Various formulations (Table no.1 and 2) and powder blends were 
studied based on different proportions of polymers, excipients and 
their manufacturing processes. Tramadol hydrochloride floating 
matrix tablets were prepared by direct compression method using 
hydrophilic polymer (different grades of PEOs or HPMC (K100M) or 
Xanthan gum) and PPM (different Eudragit®
Physical evaluation of the floating matrix tablets 
 polymer ratio and their 
concentration). Magnesium stearate was used as lubricant. Drug and 
polymers, passed through sieve No.30 mesh, were mixed uniformly 
for 5 minute in a polybag and further mixed with magnesium 
stearate for 3 minutes. The resultant mixture was then compressed 
into tablets on a 8- station rotary tablet punching machine (Kambert 
Machinery Co. Pvt. Ltd, India) using a 10.3 mm standard concave 
punches with corresponding die to provide a desirable hardness. 
The tablets were compressed at different hardness for selected 
formulation. For comparison purpose, tramadol hydrochloride 
extended release matrix tablets were prepared using Tramaol 
hydrochloride, PEO 200 mg and magnesium stearate 5 mg using 
similar manufacturing process as mentioned above. The amount of 
tramadol hydrochloride in floating tablets was kept constant at 100 
mg while the amount of other excipients was varied. 
Tablet weight variation is calculated by measuring the weight of ten 
tablets and the results are expressed as mean values±SD. The 
hardness and thickness of the matrix tablets were examined for five 
tablets of each batch using a hardness tester (Dr. Schleuniger, 
Germany) and a micrometer respectively. Friability of the tablets 
was measured in a friability tester (Electrolab, India.). The tablets 
were weighed initially and rotated at 25rpm for 4 min, and the 
samples were then reweighed. The percentage friability was 
calculated using the equation: 
F% = (W1 −W2)/ W1 × 100% ………….[1] 
where F% represents the percentage weight loss, and W1 and W2 
are the initial and final tablets weights, respectively. 
The floating lag time and the total floating time buoyancy 
The floating lag time and the total floating time were determined by 
observation of the floating behaviors in the release test using a 
dissolution tester (Electrolab, India) with the paddle method at a 
rotation speed of 50 rpm. The dissolution medium was 900 ml of 
0.1N HCl (pH 1.2), pH 6.8 phosphate buffer or deionized water at 37 
± 0.5°C. The state of the tablets during buoyancy testing was checked 
visually for 12h. The time interval between the introduction of the 
tablet into the release medium and its buoyancy to the surface was 
taken as floating lag time and the total floating time was observed 
visually. All buoyancy tests were performed in triplicate. 
In-vitro drug release 
In-vitro drug release testing from tablets was conducted according 
to the USP 27 apparatus 2 specifications using a dissolution tester 
(Electrolab, India). The dissolution testing for tramadol 
hydrochloride was conducted in 900 ml of 0.1N HCl (pH 1.2) or pH 
4.5 acetate buffer or pH 6.8 phosphate buffer. During dissolution 
testing, the media was maintained at 37±0.5°C. The paddles rotated 
at a speed of 50 rpm. The tablets were placed into 900 mL of 
dissolution medium. Aliquots of 8 mL were withdrawn from the 
dissolution apparatus at different time intervals and filtered through 
a cellulose acetate membrane (0.45 µm). The drug content was 
determined spectrophotometrically at a wavelength of 271 nm. At 
each time of withdrawal, 8 mL of fresh medium was replaced into 
the dissolution flask. The mean of three determinations was used to 
calculate the drug release from each of the formulation. 
Swelling studies 
The swelling of the polymers upon hydration by the test medium 
was determined by a method similar to the equilibrium weight gain 
method as reported earlier. The matrix tablets were weighed and 
placed in tared metallic baskets. These baskets were then immersed 
in 900 ml of pH 1.2 or pH 6.8 phosphate buffer medium, at 100 rpm 
and 37± 0.5°C (USP 25 basket method).  
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At specified time intervals, the baskets containing the matrix tablets 
were removed, lightly blotted with tissue paper so as to remove 
excess water and weighed again. They were then placed back in the 
dissolution vessel as quickly as possible. The percent degree of 
swelling was calculated as follows [35]:  
Percent degree of swelling = [(Ws – Wd) / Wd] X 100  ……….  [2] 
where Ws is the weight of the swollen matrix at time t and Wd is the 
weight of the dry matrix. The swelling study was done in triplicate 
for all samples tested. 
Drug release kinetics  
To study the release kinetics, data obtained from in-vitro drug 
release studies were plotted in various kinetic models: zero order 
(Equation 3) as cumulative amount of drug released against time 
and Higuchi’s model (Equation 4) as cumulative percentage of drug 
released against square root of time. 
Mt / M∞  = K0
Where M
 t ……………. [3] 
t / M∞ is the fraction of drug released at any time t; where 
K0
M
 is the zero-order rate constant.  
t  / M∞  = KH t1/2
where K
 …………… [4] 
H
(Q
 is the constant reflecting the design variables of the 
system and t is the time in hours. Hence, drug release rate is 
proportional to the reciprocal of the square root of time. To evaluate 
the drug release with changes in the surface area and the diameter 
of the particles/tablets, the data were also plotted using the Hixson-
Crowell cube root law: 
0) 1/3 - (Qt) 1/3 = KHC
Where Q
 t …………….. [5] 
t is the amount of drug released in time t, Q0 is the initial 
amount of the drug in the tablet, and K HC
Mechanism of drug release 
 is the rate constant for 
the Hixson-Crowell rate equation, as the cube root of the 
percentage of drug remaining in the matrix versus time. The 
following plots were made: cumulative % drug release versus time 
(zero order kinetic model); cumulative % drug release versus 
square root of time (higuchi model) and cube root of drug % 
remaining in matrix versus time (hixson-crowell cube root law). 
The model with the highest correlation coefficient was considered 
to be the best fitting one. 
To study the release kinetics from the floating matrix tablets, the 
release data were fitted to the well-known exponential equation 
(power law or Korsmeyer–Peppas equation), which is often used to 
describe the drug release behavior from polymeric systems [36]. 
Mt / M∞  = K t n
Where M
 …………………. (6) 
t / M∞
log [M
 is fraction of drug released at time t, k is the rate 
constant incorporating the structural and geometric characteristics 
of the matrix tablets and n is the release exponent indicative of the 
drug release mechanism. To clarify the release exponent for 
different batches of matrices, the log value of percentage drug 
released was plotted against log time for each batch according to the 
equation 7. 
t  /M∞
In case of fickian release (diffusionaly controlled-release), the n has 
the limiting values of 0.45 for release from cylinders. Case II 
transport or relaxation controlled delivery; the exponent n is 0.89 
for release from cylinders. The non-fickian release or anomalous 
transport of drug occurred when the n values are between the 
limiting values of fickian and Case II transport. The non-fickian 
kinetics corresponds to coupled diffusion/polymer relaxation. 
Occasionally, values of n > 0.89 for release from cylinders have been 
observed, which has been regarded as super case II kinetics [36].  
] = log k + n log t ................... [7] 
Release profiles comparison  
The drug release profiles were compared using two model-
independent methods, mean dissolution time (MDT) and similarity 
factor (f2) [37]. MDT was calculated from dissolution data using 
equation 8, and has been used for comparison.  
 ….……… [8] 
Where j is the sample number, n the number of time increments 
considered, t j
The similarities between two dissolution profiles were assessed by a 
pair-wise model independent procedure such as similarity factor 
(f2): 
 is the time at midpoint between tj and t j−1, and ΔQj the 
additional amount of drug dissolved in the period of time tj and tj−1.  
 …… [9] 
Where n is the number of pull points, Rt is the reference profile at 
time point t, and Tt
 
 is the test profile at the same time point; the 
value of f2 should be between 50 and 100. An f2 value of 100 
suggests that the test and reference profiles are identical and, as the 
value becomes smaller, the dissimilarity between release profiles 
increases. 
 
Fig. 1: FT IR spectrum of EL (a), EE (b), physical mixture (c) and 
heat treated polymer mixture (PPM) (d). 
 
 
Fig. 2: DSC spectrum of tramadol (a), EE (b), EL (c), PPM (d) and 
physical mixture of tramadol and PPM (e) 
 
 
Fig. 3: Comparative dissolution profiles showing the effect of 
different Eudragit® ratio on release of tramadol from floating 
matrix tablets. Each data point represents the average of 3 
tablets from three batches with SD within ±3.0. 
Jeganathan et al. 




Fig. 4: Comparative dissolution profiles showing the effect of 
different polymer concentration on release of tramadol from 
floating matrix tablets. Each data point represents the average 
of 3 tablets from four batches with SD within ±3.0. 
 
 
Fig. 5: Comparative dissolution profiles showing the effect of 
different PEO grades on release of tramadol from floating 
matrix tablets PEO grade. Each data point represents the 
average of 3 tablets from three batches with SD within ±3.0. 
 
 
Fig. 6: Swelling index of matrix tablet prepared with different 
PEO polymer grades (n=3). 
 
Fig. 7: Comparative dissolution profile of tramadol floating 
matrix tablet prepared with different hydrophilic polymer 
types. Each data point represents the average of 3 tablets from 
three batches with SD within ±3.0. 
 
Fig. 8: Swelling index of matrix tablet prepared with different 
hydrophilic polymer grades (n=3). 
 
 
Fig. 9: Comparative dissolution profile studies of tramadol 
floating matrix tablet prepared with different tablet hardness. 




Fig. 10: Comparative dissolution profiles showing the effect of 
dissolution medium type on release of tramadol from floating 
matrix tablets. Each data point represents the average of 3 
tablets with SD within ±3.0. 
 
 
Fig. 11: Swelling index of matrix tablet in different dissolution 
medium (0.1N HCl and pH 6.8 buffer) (n=3). 
Jeganathan et al. 




Fig. 12: Comparative dissolution profiles showing the effect of 
agitation speed on release of Tramadol from floating matrix 
tablets. Each data point represents the average of 3 tablets with 
SD within ±3.0. 
 
RESULTS AND DISCUSSION 
Characterization of thermal treated PPM 
FT-IR has been used for studying chemical interactions at a 
molecular level in polymer-polymer blends in the inter poly 
electrolyte complex field. This analysis was focused on the changes 
in bands associated with the polymers amino and carboxylate 
groups. If the two polymers ionically interacted in the complex, then 
the functional groups in the IR spectra would show the emergence of 
additional bands, alterations in the wave number position or 
broadening, compared with pure polymer spectra [38]. The FT-IR 
spectra of EL, EE powder, physical mixture of EE/ EL and treated 
PPM in a 1:1 weight ratio, respectively are shown in figure 1a-d. 
Since EE and EL belong to the same class/ derivatives of methacrylic 
acid copolymers - the FTIR spectra would exhibit many common 
features.  
EE showed a characteristic band at 1,732 cm−1
Moreover, EL also showed a wide absorption range of the associated 
hydroxyl groups between 2,500 and 3,500 cm
 which corresponds to 
absorption of ester groups in addition to two more absorption bands 
at 2,771 and 2,822 cm−1 which corresponds to the optical 
absorption due to non-ionized dimethyl amino groups [31]. On the 
other hand, the spectrum of EL showed similar but broader 
absorption band for the nonionized carboxylic acid groups at 1,732 
cm−1 than that found in EE due to the intra- and intermolecular 
hydrogen bonding between the carboxylic acid groups [39]. 
−1
 However, a possible ionic interaction between EE and EL would be 
expected to have some impact on the shape of the FT-IR spectrum. 
Figure 1d showed the FT-IR spectrum for treated PPM prepared by 
hot mixing of EE and EL. 
 but this was not 
clear from the figure; rather, several minor peaks have been 
observed in this range. As can be seen from the figure 1C, the FT-IR 
spectrum of the physical mixture EE and EL seemed to be a 
superposition of the spectra of the two polymers and no new peaks 
were observed suggesting that only minimum, if any, interaction 
could be found between EE and EL in their powdered base forms. 
 
Table 1: Composition of tramadol floating matrix tablets 
S. No. Ingredients F1 F2 F3 F4 F5 F6 F7 
1 Tramadol Hydrochloride 100 100 100 100 100 100 100 
2 Polymethacrylate mixture (1:1) -- 100 150 200 -- -- 200 
3 Polymethacrylate mixture (1:2) -- --  -- 200 -- -- 
4 Polymethacrylate mixture (2:1) -- -- -- -- -- 200 -- 
5 PEO WSR 303 200 200 200 200 200 200 100 
6 Magnesium stearate 5 5 5 5 5 5 5 
 Total (mg) 305 405 455 505 505 505 405 
 
Table 2: Composition of tramadol floating matrix tablets 
S. No. Ingredients F8 F9 F10 F11 
1 Tramadol Hydrochloride 100 100 100 100 
2 Polymethacrylate mixture (1:1) 200 200 200 200 
3 PEO WSR coagulant 200 -- -- -- 
4 PEO WSR N80 -- 200 -- -- 
5 HPMC -- -- 200 -- 
6 Xanthan gum -- -- -- 200 
7 Magnesium stearate 5 5 5 5 
 Total (mg) 505 505 505 505 
 
Table 3: Tablet physical parameters and floating properties 
Formulation code Ave weight (mg) Thickness (mm) Hardness (kp) Floating lag time  Total floating time (h) 
F1 305 ± 1.4 4.49 ± 0.02 6-8  NF NA 
F2 405 ± 1.6 5.76 ± 0.03 6-8  NF NA 
F3 455 ± 1.4 6.74 ± 0.03 7-9 2-3 s >24 
F4 505 ± 1.7 7.23 ± 0.04 8-10 2-3 s >24 
F5 505 ± 1.3 7.34 ± 0.03 8-10 2-3 s >24 
F6 405 ± 1.2 7.15 ± 0.05 8-10 2-3 s >24 
F7 505 ± 1.5 5.98 ± 0.06 8-10 2-3 s >24 
F8 505 ± 1.1 7.22 ± 0.03 8-10 2-3 s >24 
F9 505 ± 1.4 7.13 ± 0.03 8-10 2-3 s >24 
F10 505 ± 1.8 7.08 ± 0.03 8-10 NF NA 
F11 505 ± 1.6 6.75 ± 0.02 8-10 NF NA 
NF: Not floating after1h 
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Table 4: MDT and T 50 % of tramadol matrix tablets 
Formulation Code MDT  T50% 
F1 4.3 3.80 
F2 4.1 3.27 
F3 5.0 4.38 
F4 4.7 4.39 
F5 4.4 3.49 
F6 4.5 3.94 
F7 3.7 2.92 
F8 4.7 4.33 
F9 4.0 3.24 
F10 4.1 3.63 
F11 3.8 3.06 
 
Table 5: Release kinetic parameters of the selected formulation 
Formulation Code Zero order  Higuchi’s model Hixson-Crowell model Korsmeyer-Peppas model 
r K r 0 K R H K r HC Kp n -n 
F4 0.936 6.293 0.996 27.48 0.997 0.187 0.999 19.815 0.626 
 
Formation of IPC between the anionic polymer (EL) and the cationic 
polymer (EE) has been reported by various research groups. The FT-
IR spectrum of treated PPM (figure 1D) does not demonstrated any 
such formation of IPC similar to those published in the literature. 
Several authors reported that when IPC is formed between EE and 
EL, the FT-IR spectrum showed several new peaks at 1,751 and 
1,542 cm−1 
Differential scanning calorimetry 
that might be assigned to the ionized carboxylate groups 
and hydrogen bonded carbonyl groups accompanied by the decrease 
in intensity of band corresponding to the nonionized carboxylic acid 
group [30]. Further, a decrease in the intensity of the non-ionized 
dimethylamino group in addition to the formation of weak bands in 
the range of 2,770–2,830 cm−1 might be due to the interaction of 
protonated dimethylamino group from EL with carboxylate group 
from EE. Based on the above facts, it is confirmed that no such 
interactions peaks were observed in FT-IR spectrum of treated 
polymethacrylate powder mixtures. 
DSC thermogram of pure drug, EE, EL, PPM and physical mixture of 
drug and PPM are shown in figure 2a-e. EL showed a broad 
endothermic band ranging between 50 and 100°C, due to the 
polymer dehydration, followed by a second endothermic effect at 
higher temperature, attributable to the melting of its crystalline 
portion [40]. Glass transition temperature (Tg) of EE was observed 
around 50°C and no major thermal events in the thermogram 
indicated the amorphous nature of the material. For treated PPM, a 
broad endothermic peaks observed around 210°C indicated the 
reduced crystalinity of EL. Tramadol hydrochloride showed two 
endothermic peaks: one sharp peak at 180°C corresponding to the 
melting point of the drug and one broad endothermic peak around 
270 °C corresponding to the degradation of drug. There was no 
significant interaction between tramadol hydrochloride and treated 
PPM as the thermograms of the drug and treated mixture showed 
melting endotherms of similar temperatures. 
Characterization of matrix tablets 
The results indicated that all the tablets prepared in this study meet 
the USP 29 requirements for weight variation tolerance. The 
thickness and hardness variation of the individual tablet batches 
was within ± 3 SD (Table 3). The friability was found to be less than 
1%w/w for all the formulations evaluated. These results indicated 
that the direct compression method is an acceptable method for 
preparing good quality floating matrix tablets of tramadol. 
In Vitro buoyancy 
During preliminary study, matrix tablet prepared with only EE found 
to disintegrate rapidly in the pH 1.2 medium when tested for 
buoyancy. Matrix tablet prepared using physical mixture of both 
Eudragit® polymers (EE and EL) were found to float in the medium. 
However, the tablets were found to disintegrate and lost its matrix 
integrity after 3-4 hours of floating. Obeidat et al.[30-31] also 
reported the similar observations. However, matrix tablets prepared 
using treated PPM showed instant floating behavior and the matrix 
tablet integrity was found good even after 12 h of testing. Based on 
these observations, we have selected the treated PPM as floating aid 
for the preparation of floating matrix tablets. Matrix tablet prepared 
using only PEO as polymer showed no floatation in 0.1N HCl. 
Floating lag time and total floating time for the various formulations 
prepared are shown in table 3. The floating behavior of the 
formulations was found to be dependent on the concentration of 
treated PPM as well as the other polymer types used in the 
formulations. The change in ratio of Eudragit®
Drug-release studies 
 mixture and the PEO 
grade did not have any negative impact of the floatability of the 
matrix tablets prepared. Immediate floating of the tablet was 
observed in pH 1.2, pH 6.8 phosphate buffer as well as in water. This 
type of system will be considered advantageous where floating of 
the matrix tablet will occur irrespective of the gastric pH of the 
stomach.  
Effect of Eudragit®
EE and EL are quite different in solubility. Therefore, the EE/EL ratio 
in the tablet might considerably affect the hydration property and 
drug diffusion coefficient in the matrix. In order to evaluate this 
effect and to study the effect of EE/EL ratio on floating lag time, 
three formulations containing different weight ratios (1:2(F5), 
1:1(F4) and 2:1(F6)) of EE and EL were prepared. The concentration 
of treated PPM was set at a fixed quantity of 200 mg/tablet. The 
drug release profiles from these formulations are shown in figure 3. 
The release of the drug from formulation with different EE/EL ratios 
was found to be similar based on similarity factor. The f2 values 
determined by comparing drug release profiles of 1:1 ratio with 1:2 
and 2:1 were found to be greater than 63.8 and 73.9 respectively. 
The MDT and t
 ratio and their concentration 
50 % values were found to be comparatively similar 
for all the hardness range evaluated (Table 4). Floating lag time and 
total floating time were found to be similar and not affected by the 
EE/EL polymer ratios. Different concentration of treated PPM can 
also affect the floating ability, when the concentration of polymer 
mixture was under 100 mg/tablet, the floating lag time was 
significantly delayed (>1 h), the tablets were not light enough to 
float within 3 min. The floating lag time was found to be under 10s 
and the total floating time was found to be more than 24h but when 
the PPM concentration was more than 150 mg/tablet and 
compressed at the hardness levels of less than 12kp. The drug 
release profiles from formulations containing different 
concentration of polymethacrylates are shown in figure 4 and found 
to be comparable. The f2 factor values were found to be more than 
50 when the formulation without polymethacrytalte mixture was 
compared to formulations containing different concentrations of 
polymethacrylates mixtures.  
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Effect of PEO grade and concentration  
PEO is a hydrocolloid gelling agent. Upon contact with gastric fluid, 
PEO takes up water and when water penetrates the matrix, the 
polymer chains become hydrated and these eventually disentangle 
from the matrix. At high polymer concentrations, the linear polymer 
chains entangle to form what may be considered ‘virtual cross-
linking’ which eventually erodes, resulting in drug liberation. 
However, the rate of polymer erosion is dependent on the viscosity 
of the PEO grade that is used in the formulation. PEO WSR 303 has a 
high molecular weight and is of high viscosity grade, it is relatively 
resistant to polymer erosion compared to the low molecular weight 
and low viscosity grades [41]. The effect of viscosity of PEO on the 
drug release was evaluated and shown in figure. 5. The 
concentration of each type of PEO (Polyox WSR N80 (F9), Polyox 
WSR coagulant (F8) and Polyox WSR 303(F4)) was set at a fixed 
quantity of 200 mg/tablet. As the viscosity of PEO was increased 
from WSR N80 to WSR coagulant, the release rate was decreased. 
Drug release at 12 h in these formulations was 100% and 87% 
respectively. The drug release was fastest in PEO WSR N80 
formulation with a K value of 23.55% h− 0.641 and t50% value of 3.24 
h. The drug release was slowest in PEO WSR 303 formulation with a 
K value of 20.28% h −0.616 and t50
The swelling behavior of various polymer blends was analyzed to 
compare their water uptake capacity. The rate of swelling for matrix 
tablets that contained different PEO grades is shown in figure 6. 
Swelling of the matrix, which is indicated by the transition of the 
polymer from the glassy to the rubbery state, is an important 
parameter in the determination of the release characteristics of the 
matrix system [42]. The correlation of polymer swelling to drug 
release can help explain why different polymer blends gave different 
mechanisms of release. Fig.6 showed that matrices which contained 
high molecular weight PEO showed significant swelling over time 
(P<0.05). The highest degree of hydration was achieved by the 
Polyox WSR 303 tablet. There was about 300% weight gain at the 
end of 6 h due to swelling in these matrices. On the other hand, 
formulation containing low molecular weight Polyox WSR coagulant 
was hydrated to a much lower extent compared to Polyox WSR 303 
matrix tablets. These matrices could hydrate only up to 5 h after 
which there was no further increase in the tablet weight due to 
water uptake. For the Polyox WSR N80 matrix, low swelling and 
erosion of the matrix tablet was observed after 5 h.  
% value of 4.33 h. This observation 
was agreed with other reports [41]. The release rate was faster with 
lower viscosity grades of PEO, probably owing to less polymer 
entanglement and less gel strength. As it clear from the figure 5, 
there is no difference in the drug release profile between 
formulations containing Polyox WSR coagulant and Polyox WSR 303 
grades (f2 = 97).  
Effect of polymer type 
The effect of different hydrophilic polymers (Xanthan gum (F11), 
HPMC (K100M) (F10) and PEO (Polyox WSR 303) (F4) on drug 
release property was studied and shown in figure 7. The effect of 
polymer types on tablet buoyancy was also evaluated. The MDT and 
t50
The nature of the polymer plays an important role in this swelling 
process of the matrix tablets. Swelling studies were carried out, in 
order to investigate whether the extent of swelling varied for the 
different formulations. The results obtained from these swelling 
studies are represented in figure 8. From analysis of this data, it was 
possible to conclude that for the xanthan gum containing matrix 
tablets, the amount of aqueous uptake absorbed (and consequently 
the degree of swelling) was lower than for formulations containing 
HPMC or PEO. The faster drug release from the xanthan gum based 
formulations can be attributed to the low viscosity and low swelling 
of the polymer. The floating lag time was found to be higher (> 1h) 
for HPMC and Xanthan gum based formulations compared to the 
PEO based formulations (<10 seconds) compressed at the same 
hardness level (8-10 kp). 
 % values of Xanthan gum, HPMC and PEO formulations were 
found to be 3.8, 4.1, 4.7 h and 3.06, 3.63, 4.39h, respectively. The 
drug release from the formulation containing xanthan gum (F11) 
was found to be slightly faster than the formulations containing 
other two polymers. The f2 factor value was observed to be 49.67 
between Xanthan gum and PEO formulations, indicating the 
difference between the release profiles, whereas the f2 factor values 
were found to be 77.83 between HPMC and PEO formulations, 
indicating no difference between the release profiles of HPMC and 
PEO formulations. 
Effect of Hardness on Drug Release 
The effect of tablet hardness on the drug release was studied by 
preparing tablets using same type of polymer and same polymer 
proportion but with different hardness levels, 6–8, 8–10, 10-12 and 
17–18 kp. As shown in figure 9, the release of the drug from 
formulations compressed at different hardness levels were found to 
be similar based on similarity factor. The f2 values determined by 
comparing drug release profiles of 8-10 kp with 6-8 kp, 10-12 kp 
and 17-18 kp was found to be 60, 66.5 and 70.1 respectively. The 
tablets compressed at hardness levels beyond 12 kp was found to be 
non floating and indicated that the tablet density may be higher than 
1.0mg/mm3
Effect of dissolution media on drug release 
. Tablets compacted at a hardness level of less than 12 
kp, keep more entrapped air, decreasing the agglomerate density 
and allowing the tablets floating. On the other hand, tablets 
compacted at higher pressure are less porous and display a density 
not allowing the matrices floatation. 
The investigation of the effect of various dissolution media on the 
release profile of drug from the dosage form is important because 
the dosage form will encounter environments of differing pH during 
its transit in the gastrointestinal tract. The effect of dissolution 
media (pH 1.2, 4.5 and 6.8) on the drug release from selected 
formulation (F4) are shown in Fig. 10. The f2 values determined by 
comparing drug release profiles in pH 1.2 with pH 6.8, pH 4.5 with 
pH 6.8 and pH 1.2 with pH 4.5 were found to be 38.4, 62.9 and 46.0 
respectively for the selected formulation (F4); The drug release was 
fastest in pH 1.2 with a K value of 19.815% h−0.626 and t50% value of 
4.39 h. The drug release was slowest in pH 4.5 and pH 6.8 buffer 
with a K value of 17.906% h −0.553 and 18.24 % h−0.489
The observed difference in release rate in different dissolution 
medium could be attributed to differences in polymer characteristics 
in different media than due to the drug. This is because tramadol 
hydrochloride has pH independent solubility. The difference in 
dissolution profiles of selected formulation (F4) was due to the 
difference in the ionization of polymethacrylates in different 
dissolution media because of which there was a difference in 
swelling, gel strength and diffusional path length of the matrix. The 
% swelling at 6h in pH 1.2 and pH 6.8 buffer medium was found to 
be 307 % and 427 % respectively, indicated higher degree of 
swelling in the later dissolution medium and slower release rate 
(figure 11). As the pH of media increases, the ionization of carboxylic 
groups (present in the Eudragits
, t50% value of 
6.4 h and 8.4 h respectively. The values of n for the selected 
formulation (F4) in pH 1.2, 4.5 and 6.8 were found to be 0.626, 0.553 
and 0.475 respectively, indicating that the mechanism of drug 
release from the formulations across the pH range of 1.2 - 6.8 was 
found to be similar and follows non-ficikian or anomalous diffusion 
mechanism 
® polymer) increases and could 
leads to the formation of in-situ interpolyelectrolyte complexes 
between the oppositely charged Eudragit® polymers and because of 
this swelling and diffusional path length of the matrix increases. 
Formation of interpolyelectrolyte complex between the cationic 
polymer (EE) and anionic polymer (EL) has been reported by 
various research groups. Bani-Jaber et al. [32] reported that when 
sodium bicarbonate, an alkaline excipients, was added to the 
Eudragit® mixed matrix system, it provided increased in micro-
environmental pH around EL particles leading to the ionization of EL 
and consequently EE and EL complexation. Based on this, slower 
drug release rate in pH 4.5 and pH 6.8 buffer medium compared to 
drug release rate in pH 1.2, could be attributed to the formation of 
interpolyelectrolyte complex formation in these dissolution 
conditions. Ionic interaction between two oppositely charged 
polymers and subsequent in-situ interpolyelectrolyte formation was 
reported when the binary mixtures of polyvinylacetate phthalate 
and EE were exposed to pH 5.5 acetate or pH 6.8 phosphate buffer 
[43]. 
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Effect of Agitation Speed on Drug Release 
It is known that the drug release rate from the delivery system shall 
be influenced by the factors that influence dissolution such as the 
thickness of the diffusion boundary layer if it is controlled by the 
dissolution of drug. The aqueous diffusion boundary layer around 
the matrix offers significant resistance to the dissolution of poorly 
soluble drug. The thickness of the aqueous diffusion boundary layer 
is affected by the rate of agitation speeds in the dissolution medium: 
the higher the agitation rate, the thinner the aqueous diffusion 
boundary layer [44]. If the release of tramadol is solely controlled by 
its dissolution in the release medium, then increasing the agitation 
rate should accelerate the release of tramadol. The effect of agitation 
speed on the in vitro release profiles of drug from selected 
formulation (F4) in 900 ml of pH 1.2 (0.1N HCl) is shown in figure 
12. No significant difference was observed in the release rate with 
increase in agitation speed from 50 rpm to 75 rpm as indicated by 
the f2 value (f2>97). MDT and t50% values are found to be similar 
for both the agitation speed (MDT of 4.7h and t 50 % of 4.39h for 50 
rpm and MDT of 4.7h and t50
Release Kinetics 
% of 4.33 h for 75 rpm). 
To analyze the mechanism of drug release from the matrix-tablets, 
the dissolution data were fitted to various kinetic models, the 
release kinetic parameters and the fitting ability (correlation 
coefficient, r) for the selected formulation (F4) is listed in Table 5. 
The n values of 0.626 indicated an anomalous diffusion mechanism 
for this formulation. Also, both Higuchi model (Fickian) and Hixcon – 
crowell model kinetics were fitted similarly well. 
CONCLUSION 
This study examined the preparation of a floating matrix tablet 
containing Tramadol HCl using the synthetic polymer PEO and 
thermally treated polymethacrylate mixtures as retarding polymers. 
The combination of PEO and polymethacrylate mixtures was found 
to achieve optimum in vitro release and floatability. The prepared 
tablets could float within 1 min and maintain for more than 24 h. 
The drug release at 12 h was more than 85%. The uniformity of 
weight, hardness, friability, drug content were all lying within the 
limit. The matrix integrity, swelling, in vitro drug release studies, and 
kinetics of release data were shown to depend on the type and 
composition of the polymer blends with polymethacrylate mixtures. 
The buoyancy of the tablet achieved was found to be pH 
independent. Therefore, the non- effervescent floating tablets are a 
feasible approach for the sustained-release preparation of drugs, 
which have limited absorption sites in the stomach. 
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